1. Home
  2. ACXP vs RDI Comparison

ACXP vs RDI Comparison

Compare ACXP & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.36

Market Cap

6.2M

Sector

Health Care

ML Signal

HOLD

Logo Reading International Inc

RDI

Reading International Inc

HOLD

Current Price

$1.99

Market Cap

49.0M

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACXP
RDI
Founded
2017
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
49.0M
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
ACXP
RDI
Price
$1.36
$1.99
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$95.50
N/A
AVG Volume (30 Days)
82.1K
96.0K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
60.76
EPS
N/A
N/A
Revenue
N/A
$202,988,000.00
Revenue This Year
N/A
$16.25
Revenue Next Year
N/A
$4.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.31
$0.94
52 Week High
$8.34
$2.41

Technical Indicators

Market Signals
Indicator
ACXP
RDI
Relative Strength Index (RSI) N/A 48.22
Support Level N/A $1.00
Resistance Level N/A $2.41
Average True Range (ATR) 0.00 0.13
MACD 0.00 -0.05
Stochastic Oscillator 0.00 4.00

Price Performance

Historical Comparison
ACXP
RDI

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: